Philippe Houyau

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

Alain Ravaud, Christine Chevreau, Laurent Cany et al. · Journal of Clinical Oncology · 1998 · 53 citations

Life Sciences, Immunology, Oncology +17

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

Stéphane Oudard, Armelle Caty, Yves Humblet et al. · Annals of Oncology · 2001 · 46 citations · Full text

Medicine, Oncology, Pharmacology +12

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

Marc Ychou, Michel Rivoire, Simon Thézenas et al. · Journal of Clinical Oncology · 2016 · 22 citations

Medicine, Oncology, Pharmacology +17

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz et al. · European Journal of Cancer · 2020 · 18 citations

Medicine, Oncology, Pharmacology +15